Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 7/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 5/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970450 | 0.86 | GRIA1 (0.46) | GRIA1CTSLCHRNDCHRNA1CHRNG | |
| SCHEMBL21415384 | 0.85 | GRIA1 (0.46) | GRIA1CTSLCHRNDCHRNA1CHRNG | |
| SCHEMBL16656679 | 0.85 | GRIA1 (0.46) | GRIA1CTSLCHRNDCHRNA1CHRNG | |
| SCHEMBL16217709 | 0.85 | GRIA1 (0.46) | GRIA1CTSLCHRNDCHRNA1CHRNG | |
| SCHEMBL23135666 | 0.83 | CTSL (0.44) | GRIA1CTSLCHRNDCHRNA1CHRNG | |
| SCHEMBL19477907 | 0.82 | CHRND (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19477908 | 0.80 | CHRND (0.61) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL7029376 | 0.80 | MMP1 (0.51) | CTSLMMEACECPA1ACE2 | |
| SCHEMBL8022821 | 0.80 | MMP1 (0.51) | CTSLMMEACECPA1ACE2 | |
| SCHEMBL2192683 | 0.80 | CTSL (0.44) | GRIA1CTSLCHRNDCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | IONIS PHARMACEUTICALS, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2015168514-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, LDLR | GRIA1 3223/4885CTSL 1785/4885CHRND 956/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | GRIA1 2989/4885CTSL 2830/4885CHRND 3141/4885 |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | APOB, APOL1, RBM3 | GRIA1 4650/4885CTSL 951/4885CHRND 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.